Mechanisms of hepatocellular toxicity associated with dronedarone - A comparison to amiodarone

Toxicological Sciences

Volumn 131, Issue 2, 2013, Pages 480-490

  Felser, Andrea ^a,b   Blum, Kim ^a,b   Lindinger, Peter W ^a,b   Bouitbir, Jamal ^a,b   Krähenbühl, Stephan ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Apoptosis; Benzofuran derivatives; Electron transport chain; Mitochondria; Uncoupling

Indexed keywords

AMIODARONE; DRONEDARONE; FATTY ACID; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; LIVER CELL; LIVER TOXICITY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; RAT; RESPIRATORY CHAIN;

ADENOSINE TRIPHOSPHATE; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BASE SEQUENCE; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CYTOCHROMES C; DNA PRIMERS; HUMANS; LIVER; MALE; MITOCHONDRIA, LIVER; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84873821138     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs298     Document Type: Article

References (38)

1. Anonymous. (2011). In brief: FDA warning on dronedarone (Multaq). Med. Lett. Drugs Ther. 53, 17.
2. Antico Arciuch, V. G., Elguero, M. E., Poderoso, J. J., and Carreras, M. C. (2012). Mitochondrial regulation of cell cycle and proliferation. Antioxid. Redox Signal. 16, 1150-1180.
3. Begriche, K., Massart, J., Robin, M. A., Borgne-Sanchez, A., and Fromenty, B. (2011). Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 54, 773-794.
4. Bouitbir, J., Charles, A. L., Echaniz-Laguna, A., Kindo, M., Daussin, F., Auwerx, J., Piquard, F., Geny, B., and Zoll, J. (2012). Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. Eur. Heart J. 33, 1397-1407.
5. Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., Atar, D., Avezum, A., Blomström, P., Borggrefe, M., et al. (2011). Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med. 365, 2268-2276.
6. Dobrev, D., and Nattel, S. (2010). New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 375, 1212-1223.
7. Donato, M. T., Martínez-Romero, A., Jiménez, N., Negro, A., Herrera, G., Castell, J. V., O'Connor, J. E., and Gómez-Lechón, M. J. (2009). Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem. Biol. Interact. 181, 417-423.
8. Dorian, P. (2010). Clinical pharmacology of dronedarone: Implications for the therapy of atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. 15(4 Suppl.), 15S-18S.
9. Drose, S., and Brandt, U. (2012). Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 748, 145-169.
10. Fromenty, B., Fisch, C., Berson, A., Letteron, P., Larrey, D., and Pessayre, D. (1990). Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J. Pharmacol. Exp. Ther. 255, 1377-1384.
11. Fromenty, B., and Pessayre, D. (1995). Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67, 101-154.
12. Hohnloser, S. H., Crijns, H. J., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., and Connolly, S. J. (2009). Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668-678.
13. Hoppel, C., DiMarco, J. P., and Tandler, B. (1979). Riboflavin and rat hepatic cell structure and function. Mitochondrial oxidative metabolism in deficiency states. J. Biol. Chem. 254, 4164-4170.
14. Hoy, S. M., and Keam, S. J. (2009). Dronedarone. Drugs 69, 1647-1663.
15. Julian, D. G., Camm, A. J., Frangin, G., Janse, M. J., Munoz, A., Schwartz, P. J., and Simon, P. (1997). Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349, 667-674.
16. Kaufmann, P., Török, M., Hänni, A., Roberts, P., Gasser, R., and Krähenbühl, S. (2005). Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41, 925-935.
17. Kennedy, J. A., Unger, S. A., and Horowitz, J. D. (1996). Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 52, 273-280.
18. Krahenbuhl, S., Kleinle, S., Henz, S., Leibundgut, K., Liechti, S., Zimmermann, A., and Wiesmann, U. (1999). Microvesicular steatosis, hemosiderosis and rapid development of liver cirrhosis in a patient with Pearson's syndrome. J. Hepatol. 31, 550-555.
19. Lafuente-Lafuente, C., Alvarez, J. C., Leenhardt, A., Mouly, S., Extramiana, F., Caulin, C., Funck-Brentano, C., and Bergmann, J. F. (2009). Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br. J. Clin. Pharmacol. 67, 511-519.
20. Lewis, J. H., Mullick, F., Ishak, K. G., Ranard, R. C., Ragsdale, B., Perse, R. M., Rusnock, E. J., Wolke, A., Benjamin, S. B., and Seeff, L. B. (1990). Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum. Pathol. 21, 59-67.
21. Lewis, J. H., Ranard, R. C., Caruso, A., Jackson, L. K., Mullick, F., Ishak, K. G., Seeff, L. B., and Zimmerman, H. J. (1989). Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 9, 679-685.
22. Liu, Y., Fiskum, G., and Schubert, D. (2002). Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80, 780-787.
23. Mason, J. W. (1987). Amiodarone. N. Engl. J. Med. 316, 455-466.
24. Morse, R. M., Valenzuela, G. A., Greenwald, T. P., Eulie, P. J., Wesley, R. C., and McCallum, R. W. (1988). Amiodarone-induced liver toxicity. Ann. Intern. Med. 109, 838-840.
25. Mullen, P. J., Zahno, A., Lindinger, P., Maseneni, S., Felser, A., Krähenbühl, S., and Brecht, K. (2011). Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim. Biophys. Acta 1813, 2079-2087.
26. Patel, C., Yan, G. X., and Kowey, P. R. (2009). Dronedarone. Circulation 120, 636-644.
27. Rial, E., Rodríguez-Sánchez, L., Gallardo-Vara, E., Zaragoza, P., Moyano, E., and González-Barroso, M. M. (2010). Lipotoxicity, fatty acid uncoupling and mitochondrial carrier function. Biochim. Biophys. Acta 1797, 800-806.
28. Serviddio, G., Bellanti, F., Giudetti, A. M., Gnoni, G. V., Capitanio, N., Tamborra, R., Romano, A. D., Quinto, M., Blonda, M., Vendemiale, G., et al. (2011). Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic. Biol. Med. 51, 2234-2242.
29. Simon, J. B., Manley, P. N., Brien, J. F., and Armstrong, P. W. (1984). Amiodarone hepatotoxicity simulating alcoholic liver disease. N. Engl. J. Med. 311, 167-172.
30. Singh, B. N., Connolly, S. J., Crijns, H. J., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E. M., and Hohnloser, S. H. (2007). Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357, 987-999.
31. Spaniol, M., Bracher, R., Ha, H. R., Follath, F., and Krähenbühl, S. (2001). Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J. Hepatol. 35, 628-636.
32. Spaniol, M., Kaufmann, P., Beier, K., Wüthrich, J., Török, M., Scharnagl, H., März, W., and Krähenbühl, S. (2003). Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate. J. Lipid Res. 44, 144-153.
33. Stelfox, H. T., Ahmed, S. B., Fiskio, J., and Bates, D. W. (2004). Monitoring amiodarone's toxicities: Recommendations, evidence, and clinical practice. Clin. Pharmacol. Ther. 75, 110-122.
34. Troy, C. M., and Shelanski, M. L. (1994). Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc. Natl. Acad. Sci. U.S.A. 91, 6384-6387.
35. Waldhauser, K. M., Török, M., Ha, H. R., Thomet, U., Konrad, D., Brecht, K., Follath, F., and Krähenbühl, S. (2006). Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther. 319, 1413-1423.
36. Waterhouse, N. J., and Trapani, J. A. (2003). A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ. 10, 853-855.
37. Wyss, P. A., Moor, M. J., and Bickel, M. H. (1990). Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J. Pharmacol. Exp. Ther. 254, 502-507.
38. Zahno, A., Brecht, K., Morand, R., Maseneni, S., Török, M., Lindinger, P. W., and Krähenbühl, S. (2011). The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem. Pharmacol. 81, 432-441.